查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018944

癌症生物療法市場：2026-2032年全球市場預測（依治療方法、給藥途徑、應用、最終用戶和分銷管道分類）

Cancer Biological Therapy Market by Therapy Type, Administration Route, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症生物療法市場價值將達到 812.5 億美元，到 2026 年將成長至 911.7 億美元，到 2032 年將達到 1,785 億美元，年複合成長率為 11.89%。

主要市場統計數據
基準年 2025 812.5億美元
預計年份：2026年 911.7億美元
預測年份 2032 1785億美元
複合年成長率 (%) 11.89%

本報告將科學突破、營運挑戰和相關人員的優先事項納入策略規劃，整體情況了現代癌症生物療法。

癌症生物療法正處於轉型期，其特徵是分子科學、轉化平台和以患者為中心的治療路徑的融合。免疫腫瘤學、基因修飾細胞療法和標靶生技藥品的進步正在重塑臨床實踐和產業運營，促使相關人員重新評估研發、生產和商業化等各個環節的策略重點。本文概述了當前的產業格局，重點在於推動策略決策的科學轉折點、供應鏈現狀以及相關人員的期望。

找出關鍵的科學、製造和支付方主導的變革，這些變革將從根本上改變新型生物製藥的開發、製造和報銷方式。

癌症生物治療領域正經歷一系列變革性的轉變，這些變革涵蓋了從實驗室到臨床，貫穿整個價值鏈。高精度分子譜分析和新型抗原發現工具正在拓展標靶領域，並協助疫苗、基因修飾細胞產品和溶瘤平台的精準設計。載體設計、基因編輯精準度與免疫調節結構的改進，進一步推動了這項科學發展勢頭，共同提升了新型生物製藥的治療指數。隨著轉化路徑的日趨成熟，臨床試驗設計變得更加靈活，並以生物標記主導，訊號檢測速度加快，試驗的啟動或終止決策也能夠更早做出。

本研究分析了 2025 年貿易政策調整將如何影響生物製藥的供應鏈、製造地的決策以及整個生態系統對策略採購的應對措施。

美國於2025年實施的新關稅和貿易措施進一步加劇了生物製藥全球供應鏈的複雜性。隨著製造商重新評估供應商所在地和緊急儲備，原料採購、關鍵試劑的供應以及專用設備的進口再次受到嚴格審查。為此，許多相關人員正在加快供應商多元化和近岸外包策略，以維持供應的連續性並降低關稅變化帶來的風險。

這個過程闡明了治療方法、適應症、給藥途徑、最終用戶和分銷等主題中微妙的策略意義，從而明確了開發和商業化選擇。

基於細分市場的觀點揭示了生物製藥整體情況中臨床、營運和商業性差異最為顯著的領域。根據治療方法類型，該市場涵蓋多種療法，例如癌症疫苗、CAR-T細胞療法、細胞激素療法、基因療法、單株抗體和溶瘤病毒療法，單株抗體可進一步細分為嵌合體、人源型、人源化型和鼠源型。每種療法都有其獨特的研發考量和臨床應用領域。這些療法的差異會影響監管的複雜性、製造地以及證明其廣泛應用所需的臨床證據。

該工具比較了美洲、歐洲、中東和非洲以及亞太地區的創新生態系統、監管管道和准入促進因素，以幫助企業做出市場進入決策。

區域趨勢持續影響創新方向、產品生產方式，以及最重要的病患獲取途徑。在美洲，健全的臨床試驗體系、成熟的生物技術投資者基礎和完善的報銷機制，共同創造了有利於快速臨床應用和與支付方談判的環境。然而，支付方的分散性以及處方集的區域處方集，要求申辦方制定循證策略，以應對不同的入組標準和衛生經濟預期。

本分析檢視了推動生物腫瘤學領域能力建構、生產擴張和產品組合差異化的企業策略和夥伴關係趨勢。

生物治療領域的企業發展趨勢融合了專業化、協作和策略整合。大型製藥企業正日益與靈活的生物技術公司合作，以獲取前沿平台，同時發揮自身在擴大研發規模和全球商業化方面的優勢。合約研發生產機構（CDMO）在推動每種治療方法的規模化生產中發揮核心作用，許多CDMO正在擴展其能力，以支持細胞和基因治療工作流程、分析測試以及低溫運輸物流。

為研發和生產企業提供切實可行的策略步驟，以加強其產品線、擴大生產規模，並在快速發展的腫瘤生態系統中獲得報銷途徑。

產業領導者應推動一系列切實可行的舉措，以提升開發平臺、營運準備度和市場進入成果。首先，在研發早期階段優先考慮平台穩健性和流程標準化，以便在後期階段促進規模化生產、監管申報和技術轉移。投資模組化製造和檢驗的供應鏈將縮短產品交付給患者的時間，並使其能夠更靈活地應對需求波動。其次，將衛生經濟學和結果研究納入臨床項目，以確保從早期申報到產品上市，在與支付方的討論中充分體現產品的持久性和真實世界獲益。

本報告概述了綜合的一手和二手研究途徑、檢驗過程和局限性，以確保本報告的策略可信度和背景考量。

本執行摘要的研究基礎是將對行業專家、臨床研究人員、生產專家和支付方顧問的定性訪談與對同行評審文獻、監管指導文件、臨床試驗註冊資訊和企業資訊披露的系統性二次文獻回顧相結合。主要資訊透過結構化訪談收集，旨在檢驗營運假設、澄清監管解釋並揭示生產和商業化策略的實際案例。二級資訊來源的選擇是基於相關性和時效性，以確保與當前的科學和政策發展保持一致。

這概括了整合科學潛力、營運準備和相關人員合作的策略重點，以加速擴大患者獲取途徑和專案永續性。

總之，癌症生物療法正處於一個轉折點，科學預期與實際操作能力日益趨於一致，但在供應鏈韌性、監管協調和支付方接受度方面仍面臨挑戰。本執行摘要整合了近期技術進步、生產趨勢和政策發展，旨在為致力於將科學突破轉化為可及治療方法的利益相關人員明確優先事項。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症生物療法市場（依治療方法分類）

  • 癌症疫苗
  • CAR-T細胞療法
  • 細胞激素療法
  • 基因治療
  • 單株抗體
    • 嵌合體
    • 人類
    • 人性化
    • 小鼠來源
  • 溶瘤病毒療法

第9章：按給藥途徑分類的癌症生物療法市場

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第10章 癌症生物療法市場：依應用領域分類

  • 乳癌
  • 結腸癌
  • 骨髓惡性腫瘤
  • 惡性黑色素瘤
  • 非小細胞肺癌
  • 攝護腺癌

第11章 癌症生物療法市場：以最終用戶分類

  • 門診部
  • 家庭醫療保健
  • 醫院
  • 研究機構
  • 專科診所

第12章 癌症生物療法市場：依分銷管道分類

  • 直銷
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 癌症生物療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：癌症生物療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症生物療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國癌症生物療法市場

第17章：中國癌症生物療法市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corp
  • Johnson & Johnson
  • Johnson & Johnson Services, Inc,
  • Merck & Co. Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc
  • Sanofi SA
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-B72AD18D0F9C

The Cancer Biological Therapy Market was valued at USD 81.25 billion in 2025 and is projected to grow to USD 91.17 billion in 2026, with a CAGR of 11.89%, reaching USD 178.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.25 billion
Estimated Year [2026] USD 91.17 billion
Forecast Year [2032] USD 178.50 billion
CAGR (%) 11.89%

Framing the contemporary cancer biological therapy landscape by synthesizing scientific breakthroughs, operational challenges, and stakeholder priorities for strategic planning

Cancer biological therapy has entered a transitional phase defined by convergence between molecular science, translational platforms, and patient-centered care pathways. Advances in immuno-oncology, engineered cell therapies, and targeted biologics have reshaped both clinical practice and industrial operations, prompting stakeholders to re-evaluate strategic priorities across research, development, manufacturing, and commercialization. This introduction frames the contemporary landscape by highlighting the scientific inflection points, supply chain realities, and stakeholder expectations that together drive strategic decision-making.

Over recent years, developers and care providers have moved from proof-of-concept demonstrations toward scalable clinical programs and integrated care models. As a result, clinical teams and executives must reconcile long-term scientific opportunity with near-term operational constraints. In this context, research institutions, contract development organizations, and commercial manufacturers are collaborating more closely to de-risk late-stage development and enable smoother transitions to wider patient access. Consequently, leaders are prioritizing platform robustness, manufacturing agility, and evidence generation that supports regulatory and payer engagement.

The remainder of this executive summary is structured to present the transformative shifts shaping therapeutic innovation, the trade policy headwinds influencing supply chains, segmentation-informed strategic insights, regional dynamics, leading corporate behaviors, and pragmatic recommendations for industry leaders. Together, these elements provide a concise synthesis that supports informed strategy-setting and resource prioritization in a rapidly evolving field.

Identifying the pivotal scientific, manufacturing, and payer-driven transformations fundamentally altering how novel cancer biologics are developed, produced, and reimbursed

The field of cancer biological therapy is being reshaped by a set of transformative shifts that extend from bench to bedside and across value chains. High-fidelity molecular profiling and new antigen discovery tools have expanded the target space, enabling more precise design of vaccines, engineered cell products, and oncolytic platforms. This scientific momentum is complemented by enhancements in vector design, gene editing accuracy, and immunomodulatory constructs, which collectively increase the therapeutic index of novel biologics. As translational pathways mature, trial designs have become more adaptive and biomarker-driven, accelerating signal detection and enabling earlier go/no-go decisions.

Concurrently, manufacturing innovations are improving the feasibility of complex modalities. Modular and closed-system manufacturing approaches reduce contamination risk and support decentralized production models, while single-use technologies and process intensification techniques enhance throughput for cell- and gene-based therapeutics. These operational gains are fostering new commercialization approaches, including hub-and-spoke and hybrid fulfillment networks that bring specialized therapies closer to patients without compromising quality.

From a market perspective, payer engagement and health technology assessment processes are evolving to accommodate durable responses and curative potential. Real-world evidence generation and outcomes-based contracting are becoming central to reimbursement discussions, prompting sponsors to integrate long-term follow-up and health economics into early development plans. Taken together, these shifts are redefining how scientific opportunity is translated into sustainable patient access and lasting commercial value.

Analyzing how 2025 trade policy adjustments influence biological therapy supply chains, manufacturing placement decisions, and strategic sourcing responses across the ecosystem

The introduction of new tariffs and trade measures in the United States in 2025 has introduced additional complexity into global supply chains for biological therapeutics. Raw material sourcing, critical reagent availability, and the importation of specialized equipment face renewed scrutiny as manufacturers reassess vendor footprints and contingency inventories. In response, many stakeholders are accelerating supplier diversification and nearshoring strategies to preserve continuity of supply and to mitigate exposure to tariff volatility.

Beyond direct input costs, tariffs have influenced logistical planning and capital allocation. Sponsors and contract manufacturers are reevaluating the placement of high-value manufacturing assets and the trade-offs between centralized scale and regionalized resilience. As a consequence, firms are increasing investment in local regulatory expertise and in-country quality systems to streamline cross-border transfers and reduce the administrative friction associated with customs and compliance.

Strategic responses also include enhanced collaboration across the value chain. Long-term supplier agreements, co-investment in regional production capacity, and vertical integration of critical upstream capabilities have become more pragmatic ways to stabilize costs and timelines. At the policy level, industry engagement with trade authorities and participation in multilateral forums are being deployed to clarify tariff schedules and to advocate for exemptions that reflect the public health nature of many biological therapies. These combined measures aim to ensure that patient access is preserved while commercial and operational risks are actively managed.

Revealing nuanced strategic implications across modality, indication, administration route, end user, and distribution axes to sharpen development and commercialization choices

A segmentation-informed perspective clarifies where clinical, operational, and commercial differentiation is most pronounced across the biological therapy landscape. Based on therapy type, the market encompasses modalities including cancer vaccines, CAR T-cell therapy, cytokine therapy, gene therapy, monoclonal antibodies, and oncolytic viral therapy, with monoclonal antibodies further divided into chimeric, human, humanized, and murine formats, each presenting distinct development considerations and clinical niches. These modality distinctions influence regulatory complexity, manufacturing footprints, and the clinical evidence required to support broad adoption.

Based on application, biologics address a spectrum of tumor types, notably breast cancer, colorectal cancer, hematologic malignancies, melanoma, non-small cell lung cancer, and prostate cancer. Each indication has unique patient pathways and standard-of-care backdrops that shape trial design and commercial access strategies. Based on administration route, products are delivered intramuscularly, intravenously, orally, or subcutaneously, which affects patient experience, site-of-care selection, and distribution logistics. These choices, in turn, shape commercialization playbooks and patient adherence considerations.

Based on end user, the clinical ecosystem spans ambulatory care centers, home healthcare, hospitals, research laboratories, and specialty clinics, and each setting imposes different infrastructure and training requirements. Finally, based on distribution channel, therapies move through direct sales, hospital pharmacies, online pharmacies, and retail pharmacies, which dictates go-to-market models and patient support infrastructure. Understanding how these segmentation axes intersect allows leaders to prioritize investments in clinical operations, supply chain design, and stakeholder engagement that are most relevant to their specific modality and therapeutic area.

Comparing regional innovation ecosystems, regulatory pathways, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry decisions

Regional dynamics continue to shape where innovation is pursued, how products are manufactured, and the patient access pathways that matter most. In the Americas, robust clinical trial ecosystems, a mature biotech investor base, and established reimbursement frameworks create an environment that supports rapid clinical translation and payer negotiation. However, fragmentation across payers and variability in regional formularies require sponsors to design evidence strategies that address diverse coverage criteria and health economics expectations.

In Europe, the Middle East & Africa region, regulatory harmonization and centralized pathways coexist with country-level access heterogeneity. This mix necessitates tailored regulatory strategies and differentiated value dossiers that reflect local clinical practice and health system priorities. Emerging markets within the region present growing patient populations and unique unmet medical needs, but they also demand pragmatic pricing and distribution approaches that account for infrastructure constraints.

Across Asia-Pacific, governments are increasingly prioritizing domestic biopharmaceutical capability, investing in manufacturing capacity and regulatory modernization. These shifts are encouraging partnerships between multinational developers and regional manufacturers, and they are enabling accelerated approvals for therapies that address high-burden indications. Collectively, regional forces underscore the importance of adaptive market entry strategies that balance global platform advantages with nuanced local execution and stakeholder engagement.

Distilling corporate strategies and partnership dynamics that drive capability building, manufacturing expansion, and portfolio differentiation in biological oncology

Corporate behavior in the biological therapy space reflects a mix of specialization, collaboration, and strategic consolidation. Large pharmaceutical companies are increasingly partnering with nimble biotechnology firms to access cutting-edge platforms while leveraging their own strengths in development scale-up and global commercialization. Contract development and manufacturing organizations play a central role in enabling modality-specific scale, and many have expanded capabilities to support cell and gene therapy workflows, analytical testing, and cold-chain logistics.

At the same time, mid-sized and emerging companies are differentiating through niche scientific platforms, targeted indications, and novel delivery formats. These firms often pursue strategic partnerships with academic centers and clinical networks to access patient populations and translational expertise. Strategic alliances and licensing agreements remain prolific as companies seek to accelerate clinical timelines without shouldering all development risk internally. Mergers and acquisitions are typically motivated by the desire to acquire platform capabilities, expand manufacturing capacity, or secure late-stage assets that complement existing portfolios.

Investor interest remains focused on proven translational pathways and on companies that demonstrate operational readiness to scale. As a result, firms that can present integrated plans for evidence generation, manufacturing, and commercialization tend to command strategic attention from partners and acquirers alike. Overall, corporate strategies emphasize operational resilience, flexible manufacturing models, and the capacity to generate robust clinical and economic evidence.

Actionable strategic moves for developers and manufacturers to fortify pipelines, scale manufacturing, and secure reimbursement pathways in a rapidly evolving oncology ecosystem

Industry leaders should pursue a set of pragmatic actions to strengthen development pipelines, operational readiness, and market access outcomes. First, prioritize platform robustness and process standardization early in development to ease later-stage scale-up, regulatory submissions, and technology transfers. Investing in modular manufacturing and validated supply chains will reduce time to patient and allow more flexible responses to demand fluctuations. Second, embed health economics and outcomes research into clinical programs so that evidence for durability and real-world benefit informs payer discussions from initial dossier development through launch.

Third, accelerate partnerships across academia, clinical networks, and contract manufacturing organizations to share risk and to access specialized capabilities rapidly. Strategic alliances should be structured to include clear milestone-based governance and data-sharing agreements that protect intellectual property while enabling translational progress. Fourth, develop patient-centric service models that simplify administration and follow-up, such as bridging hub services, decentralized trial elements, and remote monitoring, which can improve adherence and support long-term outcome collection. Finally, engage proactively with regulators and trade authorities to anticipate policy changes, advocate for clarity on cross-border flows, and seek pathways that preserve timely patient access while maintaining safety and quality standards.

Explaining the integrated primary and secondary research approach, validation processes, and limitations that ensure the report's strategic reliability and context awareness

The research underpinning this executive summary integrates primary qualitative engagement with industry experts, clinical investigators, manufacturing specialists, and payer advisors together with systematic secondary review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures. Primary inputs were obtained through structured interviews designed to validate operational assumptions, clarify regulatory interpretation, and surface practical case examples of manufacturing and commercialization strategies. Secondary sources were selected for relevance and recency to ensure alignment with current scientific and policy developments.

Data triangulation was applied to reconcile differing perspectives and to identify consistent themes across stakeholders. Where possible, clinical outcomes and regulatory precedents were corroborated against publicly available trial records and approval documentation. Limitations of this approach include potential selection bias inherent in expert interviews and the constantly shifting nature of policy and clinical evidence, which means that readers should treat the findings as a strategic synthesis rather than an immutable prediction. To mitigate these constraints, the research emphasizes transparent assumptions and recommends periodic updates to reflect new approvals, guideline changes, and material policy shifts.

Summarizing the strategic takeaways that integrate scientific potential, operational readiness, and stakeholder alignment to accelerate patient access and program sustainability

In conclusion, cancer biological therapy stands at an inflection point where scientific promise is increasingly matched by operational capability, yet persistent challenges remain in supply chain resilience, regulatory alignment, and payer acceptance. By synthesizing recent technological advances, manufacturing trends, and policy developments, this executive summary identifies clear priorities for stakeholders seeking to translate scientific breakthroughs into accessible therapies.

Leaders that align platform development with scalable manufacturing, invest in evidence generation that addresses payer needs, and adopt flexible market entry strategies across regions will be better positioned to convert clinical success into durable patient access. Continued collaboration across industry, regulators, and clinical communities will be essential to navigate tariff-driven supply chain adjustments and to sustain momentum toward improved outcomes for patients with cancer. The combined focus on operational readiness, strategic partnerships, and patient-centered commercialization will determine which programs realize their full clinical and societal potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biological Therapy Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. CAR T-Cell Therapy
  • 8.3. Cytokine Therapy
  • 8.4. Gene Therapy
  • 8.5. Monoclonal Antibodies
    • 8.5.1. Chimeric
    • 8.5.2. Human
    • 8.5.3. Humanized
    • 8.5.4. Murine
  • 8.6. Oncolytic Viral Therapy

9. Cancer Biological Therapy Market, by Administration Route

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Cancer Biological Therapy Market, by Application

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Hematologic Malignancies
  • 10.4. Melanoma
  • 10.5. Non-Small Cell Lung Cancer
  • 10.6. Prostate Cancer

11. Cancer Biological Therapy Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Laboratories
  • 11.5. Specialty Clinics

12. Cancer Biological Therapy Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Cancer Biological Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Biological Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Biological Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Biological Therapy Market

17. China Cancer Biological Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc
  • 18.6. Amgen Inc.
  • 18.7. Astellas Pharma Inc.
  • 18.8. AstraZeneca plc
  • 18.9. Bausch Health Companies Inc.
  • 18.10. Bayer AG
  • 18.11. Biogen Inc.
  • 18.12. bluebird bio, Inc.
  • 18.13. Bristol-Myers Squibb Company
  • 18.14. Eisai Co., Ltd.
  • 18.15. Eli Lilly and Company
  • 18.16. F. Hoffmann-La Roche Ltd
  • 18.17. Gilead Sciences, Inc
  • 18.18. GlaxoSmithKline PLC
  • 18.19. Hikma Pharmaceuticals PLC
  • 18.20. Incyte Corp
  • 18.21. Johnson & Johnson
  • 18.22. Johnson & Johnson Services, Inc,
  • 18.23. Merck & Co. Inc
  • 18.24. Novartis AG
  • 18.25. Otsuka Pharmaceutical Co., Ltd
  • 18.26. Pfizer Inc
  • 18.27. Sanofi SA
  • 18.28. Spectrum Pharmaceuticals, Inc.
  • 18.29. Takeda Pharmaceutical Company Limited
  • 18.30. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)